Orbital marginal zone B-cell lymphoma of Malt: Radiotherapy results and clinical behavior
- Department of Radiation Oncology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul (Korea, Republic of)
- Department of Pathology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul (Korea, Republic of)
- Department of Ophthalmology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul (Korea, Republic of)
- Department of Hemato-oncology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul (Korea, Republic of)
Purpose: To elucidate the clinical behavior and treatment outcome of low-grade primary orbital lymphoma arising from mucosa-associated lymphoid tissue (Malt). Methods and Materials: Forty-eight patients with pathologically confirmed marginal zone B-cell lymphoma of MALT were treated with radiotherapy (RT). Thirty-eight patients (79.1%) received thorough staging workup studies including bone marrow biopsy. Radiation doses ranged from 5.4 to 30.6 Gy (median, 30.6 Gy). Median follow-up period was 70 months. Results: Only 2 patients revealed extraorbital lymphoma involvement (bone marrow, skin). Forty-six of 52 eye lesions showed complete response to RT. Six lesions demonstrated a partial response and showed gradual regression during the follow-up period of 39-72 months. Three patients experienced local recurrences at 34, 48, and 52 months after RT, which seemed to be related to improper use of the lens shield. Salvage re-RT was successful. The 10-year actuarial relapse-free survival, cause-specific survival, and overall survival rates were 93.1%, 97.9%, and 86.9%, respectively. Conclusion: Most of the MALT lymphoma of the orbit was localized at diagnosis and extraorbital relapse rarely occurred. Therefore, extensive staging workup at the time of diagnosis and follow-up studies to detect distant relapse may not be obligatory. Low-dose RT alone with proper lens shielding is the optimum treatment modality for orbital MALT lymphoma.
- OSTI ID:
- 20793479
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 65, Issue 1; Other Information: DOI: 10.1016/j.ijrobp.2005.11.035; PII: S0360-3016(05)02988-3; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Localized Orbital Mucosa-Associated Lymphoma Tissue Lymphoma Managed With Primary Radiation Therapy: Efficacy and Toxicity
Treatment Effects and Sequelae of Radiation Therapy for Orbital Mucosa-Associated Lymphoid Tissue Lymphoma